BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, released a summary of its U.S. joint venture partner, GtreeBNT’s, recent attendance at the American Academy of Ophthalmology meeting (AAO) in San Francisco, California.

Syapse today announced the appointment of Thomas D. Brown, MD, MBA as its first Chief Medical Officer. Dr. Brown, an internationally renowned oncologist and cancer researcher, joins Syapse from the Swedish Cancer Institute (SCI) at Providence St. Joseph Health (PSJH), where he served as Executive Director of SCI, and led the establishment of the SCI Personalized Medicine Program

Health Plan Chooses Cincom Eloquence to Help Streamline Member Correspondence Processes

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced the appointments of Robin A. Walker, J.D., as Senior Vice President and Chief Legal Officer, and Joan Wood as Head of Human Resources.

Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle™ in the U.S. for oral use.

Funding will support development of Credence’s Dual Chamber Reconstitution Syringe

Bertin Energy & Environment is supported by the French private sector research and assistance fund to study possible energy supply solutions for the South African part of this large radio telescope.

miRagen Therapeutics, Inc. announced new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin expression, which has been show to correlate with activation of myofibroblasts.

dMed Biopharmaceutical Co., Ltd. recently announced completion of a nearly US$50 million Series B financing, led by Vivo Capital and joined by Legend Capital, Qiming Venture Partners and Lilly Asia Ventures.

Latest round of funding, led by Atomico, will be used to build a clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism